This Month
5
0 upcoming, 5 historical review dates.
Calendar
Immovable lifecycle review calendar
0
0 post-mortem tasks pending in tasks/pending/
Completed
5
Review dates with post-mortems already ingested.
Selected Date
14 Jul 2026
Torrent Pharmaceuticals
TORNTPHARM • REVIEW_COMPLETE • value fundamental
Hold 48 days • Review / exit 14 Jul 2026
+9.49% Post-mortem done
Torrent Pharmaceuticals
TORNTPHARM • REVIEW_COMPLETE • value fundamental
Hold 48 days • Review / exit 14 Jul 2026
Torrent Pharma has fresh Q4 evidence with revenue up 42% YoY and operating EBITDA up 41%, while the stock is above its 200-DMA with bullish MACD. The PAT decline is acquisition-cost driven, so this is a selective defensive-growth add rather than a broad pharma chase.
Prices
Entry: ₹4,447.00
Current: ₹4,869.00
P&L: +9.49%
Hold Plan
Target hold: 48 days
Held so far: 79 days
Review / exit: 14 Jul 2026
Review complete
Assumptions
A1: The market continues to treat acquisition costs as transitional rather than a structural earnings reset.
A2: Price holds above the 200-DMA and does not trigger the 6% stop.
Bought 27 May 2026
Accepted from analysis task analysis-2026-05-27-0830
Confirmed and held 28 May 2026
Price remains above the 200-DMA with RSI near 56 and Q4 revenue/EBITDA growth still supporting the thesis.
Flagged for a closer look 29 May 2026
Auto-WATCH: ex_dividend event on 2026-05-29 is 0 days away
Back to normal 29 May 2026
At about Rs 4,538, the stock is above entry and above its 200-DMA with bullish MACD, so the Q4 defensive-growth thesis remains intact.
Flagged for a closer look 3 Jun 2026
At about ₹4,318, the stock is down roughly 2.9 percent from entry but still above its 200-DMA, so keep it on watch because MACD has turned bearish.
Back to normal 11 Jun 2026
TORNTPHARM closed at Rs 4,463.70, 0.4% above entry, and all tracked simple moving averages remain bullish despite a bearish short-term MACD.
Flagged for a closer look 11 Jun 2026
At Rs 4,455 the position is flat and above its Rs 3,955 200-DMA, but bearish MACD weakens the post-results continuation case.
Back to normal 12 Jun 2026
At ₹4,572.20 Torrent is 2.8% above entry and above all six tracked moving averages, preserving the defensive-growth thesis.
Flagged for a closer look 14 Jul 2026
Auto-WATCH: price ₹4947.80 reached target ₹4900.00 — review for exit
Back to normal 5 Aug 2026
Trading at Rs 4,467.90, essentially flat from Rs 4,447 entry. Technicals remain decisively bullish: RSI 57-61, MACD strongly positive, price far above 200-DMA (~Rs 2,803-3,978). Q4 revenue up 42% YoY with 41% EBITDA growth confirms the value_fundamental thesis. Cup and handle breakout pattern targets Rs 5,000-5,200. Stock eased for fifth straight session by June 18, but this is normal consolidation within an uptrend. Review date July 14 still ahead.
Flagged for a closer look 5 Aug 2026
Target price ₹4,900 EXCEEDED — stock hit ₹5,068 on Aug 5 post strong Q1 FY27 results (PAT +3.3%, revenue +55% YoY). JB Pharma integration ahead of schedule with cost synergies exceeding ₹100 Cr. Morgan Stanley upgraded to Overweight (₹5,623). However, Pharma sector faces Trump tariff overhang (100-200% on generics from 2028), semaglutide batch recall is temporary but unresolved, and stock is past review date of July 14. Target-hit action per config: move to WATCH.
Back to normal 5 Aug 2026
Up 1.2% from entry at Rs 4,499.30. JB Pharma acquisition (46.39% stake for Rs 11,917 Cr, Rs 25,689 Cr total equity value) announced June 29 is a transformative catalyst — creates a diversified healthcare platform with CDMO and ophthalmology access. Morgan Stanley upgraded to Overweight with Rs 5,623 target. Pharma sector MF flows up 30.6% YoY. Target Rs 4,900 (10%) and 6% stop intact.
Flagged for a closer look 5 Aug 2026
Target Rs 4,900 hit — closed ~Rs 4,974-5,030 (intraday high Rs 5,068.50 on Aug 5), +13% vs entry Rs 4,447; Q1 revenue +54.9% and PAT +3.3%; Morgan Stanley upgraded to Overweight TP Rs 5,623.
Back to normal 5 Aug 2026
~Rs 4,818-4,857, +8-9% from entry at Rs 4,447; NCLT sanctioned the JB merger on Jul 6 and the stock made a 52-week high of Rs 4,878.90, but RSI 74 is overbought and target Rs 4,900 is only ~1-2% away — watch for a target-hit transition.
Flagged for a closer look 5 Aug 2026
Torrent ~Rs 4,852.6 (Jul 8 snapshot) and above the Rs 4,900 target by mid-July (Rs 4,987 on Jul 16, 52-week high Rs 5,085) — target hit, so per config (target_hit_action) the position moves to WATCH; momentum cooled (RSI 74 overbought on Jul 7, ~47-54 by mid-July).
Reviewed and closed 14 Aug 2026
Post-mortem postmortem-REC-20260527-06-TORNTPHARM-2026-07-14 completed on 2026-07-14T08:30:08+05:30.
Post-Mortem
Exit correctcorrect
Review Return
Review price: ₹4,947.80
Full hold: +11.26%
Actual: +11.26%
Benchmarks
NIFTY 50: +0.61%
Excess: +10.65%
Sector excess: +6.44%
What If
Held full: +11.26%
Exited at WATCH: +1.85%
Thesis Analysis
Q4 revenue/EBITDA growth thesis held; market treated JB Chemicals acquisition costs as transitional (NCLT approval Jul 6, 52-week high). Stock stayed above 200-DMA, never threatened the 6% stop, and hit the Rs 4,900 target - a strong hit (+11.26%), beating NIFTY (+0.61%) and Nifty Pharma (+4.82%).
Exit Analysis
Target Rs 4,900 was crossed around Jul 8 and the pick was flagged for exit review at Rs 4,947.8 on the review date - consistent with target_hit_action=WATCH. No premature stop-out; timing matched the planned 48-day hold window.
Verified Assumptions
A1 Verified
Market treated JB Chemicals acquisition costs as transitional: NCLT sanctioned the merger on Jul 6, stock hit a 52-week high and the Rs 4,900 target by review date; FII stake rose to 17.97% from 15.44%.
A2 Verified
Stop never triggered - lowest price was ~Rs 4,281.5 on Jun 3 (-3.7% from entry), well above the Rs 4,180 stop. Price held above the ~Rs 3,955 200-DMA throughout and closed at Rs 4,947.8 (+11.26%).
Lessons
high earnings_quality_normalization_gate
For value_fundamental picks, a one-off/acquisition-cost-driven PAT decline should be a verify-by assumption rather than a disqualifier; the market did treat JB Chemicals costs as transitional and the stock delivered the full 10% target.
moderate N_A
Holding through WATCH flags on a value_fundamental pick inside its -7% drawdown tolerance captured the target: exiting at the first watch (May 29, Rs 4,529.1) would have banked only +1.85% versus +11.26% held to review; the transient bearish MACD in June was not a stop/exit signal.
moderate sector_tailwind_relative_strength_gate
Sector beta contributed materially - Nifty Pharma returned +4.82% over the window (June IPM sales +13% YoY per Nomura) - so the +11.26% raw return was only +6.44pp over the sector; defensive-pharma relative strength, not stock-specific alpha alone, drove the outcome.
ex dividend 29 May 2026
upcoming